Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis
N Zhang, Y Wang, G Tse… - European journal of …, 2021 - academic.oup.com
Aims To examine the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on
cardiac remodelling in patients with type 2 diabetes mellitus (T2DM) and/or heart failure …
cardiac remodelling in patients with type 2 diabetes mellitus (T2DM) and/or heart failure …
Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis
M Li, T Yi, F Fan, L Qiu, Z Wang, H Weng, W Ma… - Cardiovascular …, 2022 - Springer
Background Recent studies have shown that sodium-glucose cotransporter-2 inhibitors
(SGLT2i) can achieve significant improvement in blood pressure in people with diabetes …
(SGLT2i) can achieve significant improvement in blood pressure in people with diabetes …
Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies
E Carluccio, P Biagioli, G Reboldi, A Mengoni… - Cardiovascular …, 2023 - Springer
Abstract Background Randomized controlled trials (RCTs) reported contrasting results about
reverse left ventricular remodeling (LVR) after sodium-glucose co-transporter-2 inhibitors …
reverse left ventricular remodeling (LVR) after sodium-glucose co-transporter-2 inhibitors …
The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials
G Fan, DL Guo - European Journal of Internal Medicine, 2023 - Elsevier
Background It has been proven that sodium-glucose co-transporter 2 inhibitors (SGLT2is)
improve the prognosis of patients with heart failure, independent of the presence of diabetes …
improve the prognosis of patients with heart failure, independent of the presence of diabetes …
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with …
S Hiruma, F Shigiyama, S Hisatake, S Mizumura… - Cardiovascular …, 2021 - Springer
Background While the cardioprotective benefits of sodium-glucose cotransporter-2 (SGLT2)
inhibitors have been established in patients with cardiovascular disease (CVD), their …
inhibitors have been established in patients with cardiovascular disease (CVD), their …
Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta …
YW Yu, XM Zhao, YH Wang, Q Zhou, Y Huang… - Cardiovascular …, 2021 - Springer
Background Although the benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on
cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) …
cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) …
The obesity paradox in heart failure: is it still valid in light of new therapies?
H Fröhlich, N Frey, L Frankenstein, T Täger - Cardiology, 2022 - karger.com
Background: Obesity increases the risk of cardiovascular disease and heart failure (HF).
However, in patients with established HF, many studies observed greater survival with …
However, in patients with established HF, many studies observed greater survival with …
Could SGLT2 inhibitors improve exercise intolerance in chronic heart failure?
SN Voorrips, H Saucedo-Orozco… - International Journal of …, 2022 - mdpi.com
Despite the constant improvement of therapeutical options, heart failure (HF) remains
associated with high mortality and morbidity. While new developments in guideline …
associated with high mortality and morbidity. While new developments in guideline …
Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double …
JH Prochaska, C Jünger, A Schulz, N Arnold… - Clinical research in …, 2023 - Springer
Background The sodium-glucose co-transporter 2 inhibitor empagliflozin improves
cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure …
cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure …
The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis
Y Peng, D Qin, Y Wang, L Xue, YX Qin, X Xu - Frontiers in Physiology, 2023 - frontiersin.org
Objective: The study aimed to evaluate the effect of sodium–glucose transporter 2 (SGLT-2)
inhibitors on various parameters of exercise capacity and provide an evidence-based basis …
inhibitors on various parameters of exercise capacity and provide an evidence-based basis …